GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Bionik Laboratories Corp (OTCPK:BNKL) » Definitions » Shares Outstanding (EOP)

Bionik Laboratories (Bionik Laboratories) Shares Outstanding (EOP) : 6.88 Mil (As of Mar. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Bionik Laboratories Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Bionik Laboratories's shares outstanding for the quarter that ended in Mar. 2023 was 6.88 Mil.

Bionik Laboratories's quarterly shares outstanding increased from Dec. 2022 (6.77 Mil) to Mar. 2023 (6.88 Mil). It means Bionik Laboratories issued new shares from Dec. 2022 to Mar. 2023 .

Bionik Laboratories's annual shares outstanding increased from Mar. 2022 (6.77 Mil) to Mar. 2023 (6.88 Mil). It means Bionik Laboratories issued new shares from Mar. 2022 to Mar. 2023 .


Bionik Laboratories Shares Outstanding (EOP) Historical Data

The historical data trend for Bionik Laboratories's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionik Laboratories Shares Outstanding (EOP) Chart

Bionik Laboratories Annual Data
Trend Dec14 Dec15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.66 5.01 5.59 6.77 6.88

Bionik Laboratories Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.77 6.77 6.77 6.77 6.88

Competitive Comparison of Bionik Laboratories's Shares Outstanding (EOP)

For the Medical Care Facilities subindustry, Bionik Laboratories's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bionik Laboratories's Shares Outstanding (EOP) Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Bionik Laboratories's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Bionik Laboratories's Shares Outstanding (EOP) falls into.



Bionik Laboratories Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Bionik Laboratories  (OTCPK:BNKL) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Bionik Laboratories Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Bionik Laboratories's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Bionik Laboratories (Bionik Laboratories) Business Description

Traded in Other Exchanges
N/A
Address
80 Coolidge Hill Road, Watertown, MA, USA, 02472
Bionik Laboratories Corp is a healthcare company focused on improving the quality of life of millions of people with neurological or mobility impairments by combining artificial intelligence and innovative robotics technology to help individuals from hospital to home regain mobility, enhance autonomy, and regain self-esteem. The company uses artificial intelligence and machine learning technologies to make rehabilitation methods and processes smarter and more intuitive to deliver a greater recovery for patients with neurological or mobility impairments. Its products The InMotion ARM, and InMotion ARM/HAND are robotic therapies for the upper limbs.
Executives
Remi Gaston-dreyfus director, 10 percent owner 46 RUE PIERRE CHARRON, PARIS I0 75008
Charles Matine director 7 RUE GUSTAVE, FLAUBERT, PARIS I0 75017
Andre-jacques Auberton-herve director, officer: Chairman 18 CHEMIN DE LA VIERGE NOIRE, LA TRONCHE I0 38700
Daniel Gonsalves officer: Executive Vice President & CFO 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Loren W. Wass officer: See Remarks 34 HOG HILL ROAD, PEPPERELL MA 01463
Joseph R Martin director
Audrey Thevenon director 4500 WESTBROOK LANE, KENSINGTON MD 20895
Peter Gerald Malone director
Russo Richard Paul Jr officer: Chief Financial Officer 20 PLUNKETT WAY, TEWKSBURY MA 01876
Renaud Bertrand Maloberti officer: Chief Commercial Officer 10 ACORN WAY, GEORGETOWN MA 01833
Timothy A. Mccarthy officer: Chief Commercialization Office C/O BIONIK, 483 BAY STREET, N105, TORONTO A6 M5G 2C9
Eric Michel Dusseux director 1 RUE DU CAPOT, CALUIRE-ET-CUIRE I0 69300
Jules Marc Fried officer: VP - U.S. Operations C/O INTERACTIVE MOTION TECHNOLOGIES INC., 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Hermano Igo Krebs officer: Chief Science Officer C/O INTERACTIVE MOTION TECHNOLOGIES INC., 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Marc Mathieu director 716 BROOKS AVENUE, VENICE CA 90291